[18] 1.16 [0.73, 1.87] Subtotal (95% CI) 1.18 [0.84, 1.65] Total events Heterogeneity: [[tau].sup.2] = 0.07, [chi square] = 9.54, df = 6 (P = 0.15); [I.sup.2] = 37% Test for overall effect: Z = 0.95 (P = 0.34) Total (95% CI) 1.20 [0.89, 1.62] Total events Heterogeneity: [[tau].sup.2] = 0.09, [chi square] = 15.34, df = 9 (P = 0.08); [I.sup.2] = 41% Test for overall effect: Z = 1.20 (P = 0.23) Test for subgroup differences: [chi square] = 0.01, df = 1(P = 0.92); [I.sup.2] = 0% (b) Figure 5: Coronary angiography outcomes between the DEB group and DES group: (a) MLD; (b) late loss; (c)

binary restenosis; (d) DS%.

Compared with the BMS group, SES-treated lesions were associated with significantly higher rates of primary patency at 3 years (hazard ratio (HR) 4.81; confidence interval (CI) 2.91 - 7.94; p<0.001), as well as lower rates of

binary restenosis (HR 0.38; CI 0.25 - 0.58; p<0.001), and fewer clinically driven reintervention events (HR 0.39; CI 0.20-0.77; p=0.006).

The

binary restenosis rate was reduced by 75 percent among patients who received a therapeutic dose.

The primary endpoint of the study is

binary restenosis at nine months, a measure of vessel renarrowing.